Pfizer Italia S.r.l.

Nerviano Medical Sciences S.r.l.

Jürgen Moll

Daniele Fancelli

Mario Varasi

Paola Vianello

Barbara Forte

Tiziano Bandiera

Maurizio Pulici

Furo[3,2-c]pyrazole derivatives of formula (I) as defined in the description, and pharmaceutically acceptable salts thereof, wherein A is an aryl or heteroaryl ring, &#x2014;NHZRis at the ortho position to the CONH linker; &#x2014;Rand Rare the same or different and, independently from each other, represent a hydrogen atom, or an organic residue; Ris a hydrogen or halogen atom or an organic group; Ris a hydrogen or halogen atom or an organic group; Z is direct bond, &#x3e;C&#x2550;O, or &#x2014;C(&#x2550;O)NH&#x2014;; &#x2014;Ris hydrogen or an optionally substituted organic group or isomers, tautomers, carriers, metabolites, prodrugs, and pharmaceutically acceptable salts thereof. A process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, in particular Aurora kinases activity or IGF-1R activity, like cancer. 

1H-furo[3,2-C]pyrazole compounds useful as kinase inhibitors

Pyrrolo[3,4-c]pyrazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Growing community of inventors

Appiano Gentile, Italy

Jürgen Moll